

## Differing presenting features of idiopathic intracranial hypertension in the UK and US

Blanch, R J; Vasseneix, C; Liczkowski, A; Yiangou, A; Aojula, A; Micieli, J A; Mollan, S P; Newman, N J; Biousse, V; Bruce, B B; Sinclair, A

DOI:

[10.1038/s41433-019-0359-5](https://doi.org/10.1038/s41433-019-0359-5)

License:

None: All rights reserved

*Document Version*

Peer reviewed version

*Citation for published version (Harvard):*

Blanch, RJ, Vasseneix, C, Liczkowski, A, Yiangou, A, Aojula, A, Micieli, JA, Mollan, SP, Newman, NJ, Biousse, V, Bruce, BB & Sinclair, A 2019, 'Differing presenting features of idiopathic intracranial hypertension in the UK and US', *Eye (London, England)*, vol. 33, no. 6, pp. 1014-1019. <https://doi.org/10.1038/s41433-019-0359-5>

[Link to publication on Research at Birmingham portal](#)

### **Publisher Rights Statement:**

Checked for eligibility: 05/07/2019

This document is the Author Accepted Manuscript version of a published work which appears in its final form in *Eye*. The final version of record can be found at: <https://doi.org/10.1038/s41433-019-0359-5>

### **General rights**

Unless a licence is specified above, all rights (including copyright and moral rights) in this document are retained by the authors and/or the copyright holders. The express permission of the copyright holder must be obtained for any use of this material other than for purposes permitted by law.

- Users may freely distribute the URL that is used to identify this publication.
- Users may download and/or print one copy of the publication from the University of Birmingham research portal for the purpose of private study or non-commercial research.
- User may use extracts from the document in line with the concept of 'fair dealing' under the Copyright, Designs and Patents Act 1988 (?)
- Users may not further distribute the material nor use it for the purposes of commercial gain.

Where a licence is displayed above, please note the terms and conditions of the licence govern your use of this document.

When citing, please reference the published version.

### **Take down policy**

While the University of Birmingham exercises care and attention in making items available there are rare occasions when an item has been uploaded in error or has been deemed to be commercially or otherwise sensitive.

If you believe that this is the case for this document, please contact [UBIRA@lists.bham.ac.uk](mailto:UBIRA@lists.bham.ac.uk) providing details and we will remove access to the work immediately and investigate.

## **Differing presenting features of idiopathic intracranial hypertension in the UK and US**

Blanch RJ<sup>1,2,3,4</sup>, Vasseneix C<sup>1</sup>, Liczkowski, A<sup>5</sup>, Yiangou A<sup>5,6</sup>, Aojula A<sup>5,6</sup>, Micieli JA<sup>1</sup>, Mollan SP<sup>4</sup>, Newman NJ<sup>1,7,8</sup>, Biousse V<sup>1,8</sup>, Bruce BB<sup>1,8\*</sup>, Sinclair A<sup>5,6\*</sup>

Blanch: [orcid.org/0000-0002-6142-3280](https://orcid.org/0000-0002-6142-3280)

Mollan: [orcid.org/0000-0002-6314-4437](https://orcid.org/0000-0002-6314-4437)

Biousse: [orcid.org/0000-0002-3594-850X](https://orcid.org/0000-0002-3594-850X)

Sinclair: [orcid.org/0000-0003-2777-5132](https://orcid.org/0000-0003-2777-5132)

1. Department of Ophthalmology, Emory University, Atlanta, GA

2. Neuroscience and Ophthalmology, Institute of Inflammation and Ageing, University of Birmingham, Birmingham, UK

3. Academic Department of Military Surgery and Trauma, Royal Centre for Defence Medicine, Birmingham, UK

4. Department of Ophthalmology, University Hospital Birmingham NHS Trust, Birmingham, UK

5. Metabolic Neurology, Institute of Metabolism and Systems Research, University of Birmingham, Birmingham, UK

6. Department of Neurology, University Hospital Birmingham NHS Trust, Birmingham, UK

7. Department of Neurological Surgery, Emory University, Atlanta, GA

8. Department of Neurology, Emory University, Atlanta, GA

\*joint senior authors

Corresponding Authors: (1), Lt Col Richard Blanch, Royal Centre for Defence

Medicine, [blanchrj@bham.ac.uk](mailto:blanchrj@bham.ac.uk); (2), Dr Alexandra Sinclair, University of Birmingham, Alexandra

Sinclair, [A.B.Sinclair@bham.ac.uk](mailto:A.B.Sinclair@bham.ac.uk)

### **Conflict of interest**

The authors declare no conflict of interest.

### **Funding**

AJS is funded by an NIHR Clinician Scientist Fellowship (NIHR-CS-011-028) and by the Medical Research Council, UK (MR/K015184/1). IHH:Life database is funded by the Healthcare Quality Improvement Partnership (HQIP). The Emory cohort study was supported in part by an unrestricted departmental grant (Department of Ophthalmology) from Research to Prevent Blindness, Inc., New York, and by NIH/NEI core grant P30-EY006360 (Department of Ophthalmology). VB received research support from NIH/PHS (UL1-RR025008). NJN is a recipient of the Research to Prevent Blindness Lew R. Wasserman Merit Award. CV is the recipient of the Philippe Foundation Inc. grant.

## **Abstract**

Demographic factors potentially influencing the presentation and severity of IIH in US vs UK populations include obesity and ethnicity. We aimed to compare the presenting features of IIH between populations in UK and US tertiary referral centres, to assess what population differences exist and whether these cause different presentations and impact on visual function.

## **Methods**

Clinical data were collected on 243 consecutive UK IIH patients and 469 consecutive US IIH patients seen after 2012 in two tertiary centers. Visual function was defined as severe visual loss when HVF-MD was  $<-15$ dB, GVF showed constriction or visual acuity was less than 20/200.

## **Results**

US patients were more commonly of self-reported black race (58.9%vs7.1%) than UK patients, but had a similar mean BMI ( $38.3\pm0.63$  kg/m<sup>2</sup> UK vs  $37.7\pm0.42$  kg/m<sup>2</sup> US;  $p=0.626$ ). The UK cohort had lower presenting Frisén grade (median 1 vs 2;  $p<0.001$ ) and severe visual loss less frequently (15.4%vs5%;  $p=0.014$ ) but there was no difference in mean CSF-OP ( $35.8\pm0.88$  cmH<sub>2</sub>O UK vs  $36.3\pm0.52$  cmH<sub>2</sub>O US;  $p=0.582$ ). African-Americans had poorer visual outcomes compared with US-whites (19.4% vs 10% severe visual loss;  $p=0.011$ ). Visual function was weakly associated with CSF opening pressure ( $R^2=0.059$ ;  $p=0.001$ ), which was similar between UK and US patients.

## **Conclusions**

The UK and the US cohorts had a similar average presenting BMI. However, the worse presenting visual function in the US IIH cohort was partially attributable to differences in the black populations in the two countries.

## **Introduction**

Idiopathic Intracranial Hypertension (IIH) is a rare disease, where there is international acceptance on diagnosis,<sup>1</sup> but until recently less consensus on management.<sup>2,3</sup> Thus management may vary amongst treatment centres and, in addition, the presenting phenotype may be location-specific.

Demographic factors that potentially influence the phenotype between IIH populations are body mass index (BMI) and ethnicity. IIH is known to have a marked association with those who are obese. In particular truncal fat mass and higher BMI has been associated with more severe visual loss.<sup>4,5</sup> Obesity affects 30.4% of British women and 38.2% of American women<sup>6</sup> (Table 1). Previous work has identified that those of African-American descent with IIH are more likely than white US IIH patients to have severe visual loss,<sup>7</sup> and 2.81% of the British population identified as black on the latest census data, compared with 13.4% in the US.<sup>8,9</sup>

IIH incidence is rising in England and worldwide<sup>10,11</sup>, presumed to be related to the increasing global prevalence of obesity (Table 1).<sup>11,12</sup> The rise in CSF shunting procedures in the US between 1998 and 2002, paralleled the rise in obesity rates over that same period.<sup>13</sup> The international prevalence of IIH associates with the prevalence of obesity.<sup>11,14</sup> However, the proportion of obesity in IIH cohorts may vary independently of the overall population prevalence of obesity (Table 1). Given the differences between the UK and US populations, we aimed to compare two large neuro-ophthalmology IIH clinic cohorts from prospectively held databases in the two countries to assess for differences in the presenting phenotype.

## **Methods**

The study was approved by the University Institutional Review Board at Emory and the local NHS National Research Ethics Committee (14/LO/1208) and conformed to the tenets of the Declaration of Helsinki.

We included consecutive patients over the age of 16 with a diagnosis of IIH, seen in one US and one UK tertiary referral centres. Only patients with a diagnosis of IIH according to the modified Dandy criteria were included<sup>1</sup>: specifically papilledema, normal neurologic examination except cranial nerve palsies, normal neuroimaging, normal CSF constituents and elevated lumbar puncture opening pressure (>25cm CSF). The US cohort was a retrospectively collected cohort of consecutive patients evaluated in a standardised fashion by VB, NN and BB. The UHB cohort was prospectively collected in consecutive patients with a diagnosis of IIH who consented to recruitment in the IIH: Life database.

All patients were evaluated in a standardised manner by experienced neuro-ophthalmologists including complete neuro-ophthalmic history and examination with formal visual fields, fundus photography, neuro-imaging, height and weight. UK data were collected and entered prospectively into the IIH:life database. US data was entered retrospectively from the electronic patient record and written notes.

Data collected included age, race, gender, BMI, recent weight gain, presenting symptoms (headache, tinnitus, diplopia, transient visual obscurations), visual acuity (VA), visual fields (VF), and CSF-opening pressure (CSF-OP).

US patients' fundus images taken at or close to the time of initial presentation were Frisén-graded by 3 different neuro-ophthalmologists, all masked to clinical details. For the UK dataset, 2 different neuro-ophthalmologists performed Frisén-grading on slit lamp examination at presentation<sup>28</sup>.

Disagreements were settled by referral to two additional observers. UK patients' disc appearance was graded in clinic at the time of recruitment by two experienced neuro-ophthalmologists. Visual fields were graded as severe visual loss when the Humphrey Visual Field Mean Deviation was <-15 dB or when Goldmann visual fields showed severe constriction.

Patients who reported use of medications that have been associated with intracranial hypertension were excluded (fluoroquinolone and tetracycline antibiotics, cyclosporin, vitamin A preparations, recent steroid discontinuation). Alternative causes for intracranial hypertension were excluded at the time of diagnosis by full blood count checking for anaemia and review of imaging, including venography.

Statistical analysis was performed in SPSS 21 (IBM Corp., Armonk, NY) and used t-test for continuous numeric data and Chi-squared for categorical data except for visual fields and visual acuity data. Because visual fields (MD) and visual acuity had two measurements per patient, they were analysed using generalised estimating equations. To allow model fit, groups with few patients (e.g. transgender, South Asian race) were collapsed and combined. In particular missing race data were combined with white race, because most patients with missing race data were from the UK cohort. To assess systemically the effect of these missing data, the data were also replaced with multiple imputation and pooled analyses are reported. To minimise the risk of type 1 error, we analysed Frisén grading and severe visual field loss analysis, which are non-numeric data, for the worse eye only using Chi-squared tests. Means are reported as mean  $\pm$  standard error of the mean unless otherwise specified.

## **Results**

### **Presenting Demographics**

Consecutive cohorts of 243 UK patients and 469 US patients presenting for evaluation of IIH after 2012 in two tertiary centers were included. One patient in the UK cohort was not included because she did not consent to inclusion in IIH: Life.

US patients were more commonly of self-reported black race (58.9%vs7.1%; Table 2) and UK patients were more commonly of South Asian descent (8.8%vs1.0%), reflecting the ethnicity of the local populations surrounding the treatment centres.

There was no evidence that the UK and US patients differed in BMI ( $38.3 \pm 0.63 \text{ kg/m}^2$  UK vs  $37.7 \pm 0.42 \text{ kg/m}^2$  US;  $p=0.626$ ; 95% CI for the difference -0.8 to 2.1) or in the proportion of obese patients (84.4% UK vs 79.7% US;  $p=0.147$ ).

The gender proportions were similar between UK and US patients (6% males US vs 4.1% UK;  $p=0.284$ ).

### Visual Function

Compared with US patients (Table 2), the UK cohort had better presenting VA (logMAR  $0.09 \pm 0.02$  vs  $0.15 \pm 0.02$ ;  $p<0.001$ ) and mean deviation ( $-4.74 \pm 0.40$  vs  $-6.52 \pm 0.35 \text{ dB}$ ;  $p<0.001$ ). Frisén grade was also lower in UK patients (median 1 vs 2;  $p<0.001$ ). Because of the potential for systematic differences in how visual acuity and visual fields are assessed, we also looked at the proportion with severe visual loss, defined as diffusely constricted Goldmann visual fields or a MD  $< -15 \text{ dB}$ , as previously described.<sup>16</sup> The US patients were more likely to have severe VF loss at presentation (15.4% vs 5%;  $p=0.014$ ).

There was no evidence of a difference in mean CSF-OP between UK and US patients ( $35.8 \pm 0.73 \text{ cmH}_2\text{O}$  UK vs  $36.3 \pm 0.46 \text{ cmH}_2\text{O}$  US;  $p=0.582$ ).

### History

Among symptomatic US patients, the mean reported duration of symptoms was  $10.0 \pm 0.64$  weeks; equivalent data on symptom duration were not available in the UK cohort. The prevalence of headache as a presenting symptom was higher in UK than US patients (Table 3; 85% vs 65%;  $p<0.001$ ). Incidental finding of papilledema on routine examination was also more common in UK than US patients (Table 3; 48% vs 30%;  $p<0.001$ ). About half of the patients reported recent weight gain (54% UK vs 46% US;  $p=0.236$ ).

### Variation in visual function at presentation

150 When the US and UK datasets were analysed together, Frisén grade and CSF opening pressure were  
151 weakly associated ( $R^2=0.109$ ,  $p<0.001$ ). CSF opening pressure was available on 539/712 patients  
152 (76%) and initial Frisén grade on 288/712 patients (40%). When Frisén grade, CSF opening pressure,  
153 race, country, BMI and duration of symptoms were analysed together, CSF opening pressure and the  
154 interaction between race and country were independently associated with visual function at  
155 presentation (Table 4), assessed as mean deviation ( $R^2=0.042$ ,  $p<0.001$ ).

156



The binary measure of visual function “severe visual loss in either eye” associated with race ( $p=0.02$ ) and CSF opening pressure ( $p<0.001$ ), but a model could not be fitted for the interaction term. ( $p<0.001$ ; GEE binomial logit).

To assess the effect of missing data, multiple imputation of the missing values with pooled analysis of the 10 imputed datasets yielded results consistent with the primary analysis: every 1cmH<sub>2</sub>O increase in CSF opening pressure was associated with a 0.168dB reduction in MD ( $p<0.001$ ) and visual function was worse in African-American than white US patients by an average of 1.60dB ( $p=0.018$ ), whereas UK African Caribbean visual function was, on average, 3.15dB better than in US white patients ( $p=0.039$ ).

#### Race

Within the US cohort, African-American patients had a higher proportion of severe visual loss at presentation (19.4% vs 10%;  $p=0.011$ ) and a worse mean deviation on visual field testing ( $-7.38\pm0.52$  vs  $-5.58\pm0.49$  dB;  $p=0.003$ ). There was weak evidence of a difference in CSF opening pressure, which was higher in African-American patients ( $37.69\pm0.720$  cmH<sub>2</sub>O vs  $34.95\pm0.794$  cmH<sub>2</sub>O;  $p=0.055$ ), though minimal evidence of a difference in Frisén grade (median 3 African American vs 2 white;  $p=0.205$ ). There was no difference in presenting visual acuity (logMAR  $0.14\pm0.03$  white vs logMAR  $0.17\pm0.03$  African American;  $p=0.857$ ). On average white patients had a longer duration of symptoms before presentation ( $11.5\pm1.13$  weeks vs  $9.02\pm0.75$  weeks;  $p=0.042$ ), but no difference in the proportion of patients with incidentally discovered papilloedema (24.1% African American vs 26.3% white;  $p=0.624$ ).

There were 8 African Caribbean patients in the UK dataset, who had lower CSF opening pressures ( $33.4\pm1.81$  vs  $39.6\pm2.11$  cmH<sub>2</sub>O;  $p=0.037$ ) and better mean deviations on Humphrey visual field testing ( $-2.02$  dB $\pm0.63$  vs  $-6.02$  dB $\pm0.85$ ;  $p=0.001$ ).

#### Discussion

This collaborative study compared two large neuro-ophthalmology IIH clinic cohorts from prospectively held databases in the UK and the US and assessed for differences in the presenting phenotype between the two centres. US patients with IIH presented with significantly worse visual function, being more likely to have severe visual loss at presentation. African-American patients in the US cohort had worse visual function than white patients, who had similar baseline features in both the US and UK cohorts.

The more severe disease in African-American patients has been previously reported,<sup>7</sup> and does not seem to be explained by different access to care in our cohort, because duration of symptoms and incidentally discovered papilledema was not different between white and African-American ethnicities. Although duration of symptoms was not available in the UK cohort, there was a higher rate of incidental papilledema compared with the US cohort. The higher prevalence of incidental papilloedema in the UK cohort is in contrast to the higher reported rate of headache in the UK and could be explained by access to care, as greater access to eye examinations may be expected to associate with greater incidental detection of papilloedema. .

Visual function was similar in white US and white UK patients (0.76dB worse in US,  $p=0.192$ ), in contrast to a previous comparison between white US and white French patients with IIH,<sup>16</sup> which found that white US patients had a longer pre-diagnosis duration of symptoms and were more likely to have visual field constriction and poor visual acuity at presentation.

Table 1 shows a weak relationship between population obesity in the general population and IIH patients. A recent English paper reports not only an increase in the incidence of IIH between 2002 and 2016, but the association with obesity over this time.<sup>10</sup> In Iowa in 1988, the mean weight in an IIH population was 38% above ideal weight for height (BMI 34.5) and 67% were obese.<sup>29</sup> At that time, 17.5% of the US population was obese. Comparison with the recent IIH cohorts suggests that the average weight of IIH patients has increased over time in concert with the increased prevalence of obesity in the population. In the Idiopathic Intracranial Hypertension Treatment Trial (IIHTT), the

mean initial BMI was much higher, at 39.9, and in this trial recruitment was restricted to mild visual field defects with mean deviations less than 7 dB, although the study did not report the characteristics of patients declining to participate or failing screening.<sup>30</sup>

The US has higher prevalences of both overweight and obesity than the UK (UK 68.6% male and 58.9% female overweight, 26.9% male and 28.6% female obese; US 72.7% male and 63.2% female overweight, 35.5% male and 37% female obese). The similar weights and proportions of obesity between US and UK IIH patients probably reflects that fact that only obese patients suffer from IIH and we do not have data on the average BMI of obese patients in the UK and US. The equivalent average BMI in our US and UK IIH cohorts excludes degree of obesity as an explanatory factor in the more severe presentation of US patients.

Similar to previous studies, most IIH patients were female.<sup>18, 31</sup> In contrast to weight and gender, the racial mix of patients reflects the population local to the treatment centres, suggesting that whilst being African American confers a worse prognosis, it does not affect the risk of disease.

The relationship between Frisén grade and CSF-OP has been previously reported in the IIHTT,<sup>32</sup> although there was no relationship between CSF-OP and baseline visual function in the IIHTT, which may be related to the exclusion of patients with severe visual loss from that population. The association between high CSF-OP and visual loss has not been previously reported except that cases series of patients with fulminant disease have reported high CSF-OP.<sup>33</sup> CSF-OP may affect visual function secondary to the association between Frisén grade and visual function, but does not appear to explain the observed UK-US differences and, with  $R^2 < 0.1$ , has a modest effect.

## **Conclusions**

Visual loss at presentation was more severe in the US cohort, despite similar BMIs and similar LP pressures. The population differences in presenting visual function may relate to the higher proportion of patients of black race in the US population.

## **Conflicts**

No authors have any conflict of interest with the published work.

## **Funding**

AJS is funded by an NIHR Clinician Scientist Fellowship (NIHR-CS-011-028) and by the Medical Research Council, UK (MR/K015184/1). IIH:Life database is funded by the Healthcare Quality Improvement Partnership (HQIP). The Emory cohort study was supported in part by an unrestricted departmental grant (Department of Ophthalmology) from Research to Prevent Blindness, Inc., New York, and by NIH/NEI core grant P30-EY006360 (Department of Ophthalmology). VB received research support from NIH/PHS (UL1-RR025008). NJN is a recipient of the Research to Prevent Blindness Lew R. Wasserman Merit Award. CV is the recipient of the Philippe Foundation Inc. grant.

## **References**

1. Friedman DI, Liu GT, Digre KB. Revised diagnostic criteria for the pseudotumor cerebri syndrome in adults and children. *Neurology* 2013; **81**(13): 1159-1165.
2. Markey KA, Mollan SP, Jensen RH, Sinclair AJ. Understanding idiopathic intracranial hypertension: mechanisms, management, and future directions. *Lancet Neurol* 2016; **15**(1): 78-91.
3. Mollan SP, Davies B, Silver NC, Shaw S, Mallucci CL, Wakerley BR *et al*. Idiopathic intracranial hypertension: consensus guidelines on management. *J Neurol, Neurosurg Psychiatry* 2018.

- 252 4. Hornby C, Botfield H, O'Reilly MW, Westgate C, Mitchell J, Mollan SP *et al.* Evaluating the Fat  
 253 Distribution in Idiopathic Intracranial Hypertension Using Dual-Energy X-ray Absorptiometry  
 254 Scanning. *Neuroophthalmology* 2018; **42**(2): 99-104.
- 255
- 256 5. Szewka AJ, Bruce BB, Newman NJ, Biousse V. Idiopathic intracranial hypertension: relation  
 257 between obesity and visual outcomes. *J Neuroophthalmol* 2013; **33**(1): 4-8.
- 258
- 259 6. Ng M, Fleming T, Robinson M, Thomson B, Graetz N, Margono C *et al.* Global, regional, and  
 260 national prevalence of overweight and obesity in children and adults during 1980-2013: a  
 261 systematic analysis for the Global Burden of Disease Study 2013. *Lancet* 2014; **384**(9945):  
 262 766-781.
- 263
- 264 7. Bruce BB, Preechawat P, Newman NJ, Lynn MJ, Biousse V. Racial differences in idiopathic  
 265 intracranial hypertension. *Neurology* 2008; **70**(11): 861-867.
- 266
- 267 8. Statistics OfN. 2011 Census: Key Statistics for Birmingham and it's constituent areas. London:  
 268 Office for National Statistics; 2012.
- 269
- 270 9. Bureau USC. Population estimates, July 1, 2017, (V2017). Available  
 271 at: <https://www.census.gov/quickfacts/fact/table/US/PST045217>. Accessed 17/07/2018.
- 272
- 273 10. Mollan SPA, M.; Evison, F.; Frew, E.; Sinclair, A. J.;. The expanding burden of Idiopathic  
 274 Intracranial Hypertension. *Eye* 2018.

275

276 11. McCluskey G, Doherty-Allan R, McCarron P, Loftus AM, McCarron LV, Mulholland D *et al.*  
 277 Meta-analysis and systematic review of population-based epidemiological studies in  
 278 idiopathic intracranial hypertension. *Eur J Neurol* 2018; **25**(10): 1218-1227.

279

280 12. Mollan SP, Ali F, Hassan-Smith G, Botfield H, Friedman DI, Sinclair AJ. Evolving evidence in  
 281 adult idiopathic intracranial hypertension: pathophysiology and management. *J Neurol,*  
 282 *Neurosurg Psychiatry* 2016; **87**(9): 982-992.

283

284 13. Curry WT, Jr., Butler WE, Barker FG, 2nd. Rapidly rising incidence of cerebrospinal fluid  
 285 shunting procedures for idiopathic intracranial hypertension in the United States, 1988-  
 286 2002. *Neurosurgery* 2005; **57**(1): 97-108; discussion 197-108.

287

288 14. Chen J, Wall M. Epidemiology and risk factors for idiopathic intracranial hypertension. *Int*  
 289 *Ophthalmol Clin* 2014; **54**(1): 1-11.

290

291 15. Lichtenberg I, Blackwood E, Gordon J, Hammond S, Hawke S. The prevalence of idiopathic  
 292 intracranial hypertension and associated co-morbidities in central western new south wales  
 293 (nsw). *J Neurol, Neurosurg Psychiatry* 2017; **88**(5): e1-e1.

294

295 16. Mrejen S, Vignal C, Bruce BB, Gineys R, Audren F, Preechawat P *et al.* Idiopathic intracranial  
 296 hypertension: a comparison between French and North-American white patients. *Rev Neurol*  
 297 *(Paris)* 2009; **165**(6-7): 542-548.

298

- 299 17. Gafoor VA, Smita B, Jose J. Long-term Response of Cerebrospinal Fluid Pressure in Patients  
300 with Idiopathic Intracranial Hypertension - A Prospective Observational Study. *Ann Indian*  
301 *Acad Neurol* 2017; **20**(3): 220-224.
- 302
- 303 18. Rosenblatt A, Klein A, Roemer S, Borruat FX, Meira D, Silva M *et al*. Idiopathic Intracranial  
304 Hypertension-A Comparison of Clinical Characteristics Between 4 Medical Centers in  
305 Different Geographic Regions of the World. *J Neuroophthalmol* 2016; **36**(3): 280-284.
- 306
- 307 19. Kesler A, Gadoth N. Epidemiology of idiopathic intracranial hypertension in Israel. *J*  
308 *Neuroophthalmol* 2001; **21**(1): 12-14.
- 309
- 310 20. Yabe I, Moriwaka F, Notoya A, Ohtaki M, Tashiro K. Incidence of idiopathic intracranial  
311 hypertension in Hokkaido, the northernmost island of Japan. *J Neurol* 2000; **247**(6): 474-475.
- 312
- 313 21. Contreras-Martin Y, Bueno-Perdomo JH. Idiopathic intracranial hypertension: descriptive  
314 analysis in our setting. *Neurologia* 2015; **30**(2): 106-110.
- 315
- 316 22. Sundholm A, Burkill S, Sveinsson O, Piehl F, Bahmanyar S, Nilsson Remahl AIM. Population-  
317 based incidence and clinical characteristics of idiopathic intracranial hypertension. *Acta*  
318 *Neurol Scand* 2017; **136**(5): 427-433.
- 319
- 320 23. Raoof N, Sharrack B, Pepper IM, Hickman SJ. The incidence and prevalence of idiopathic  
321 intracranial hypertension in Sheffield, UK. *Eur J Neurol* 2011; **18**(10): 1266-1268.

322

323 24. Friesner D, Rosenman R, Lobb BM, Tanne E. Idiopathic intracranial hypertension in the USA:  
 324 the role of obesity in establishing prevalence and healthcare costs. *Obes Rev* 2011; **12**(5):  
 325 e372-380.

326

327 25. Daniels AB, Liu GT, Volpe NJ, Galetta SL, Moster ML, Newman NJ *et al*. Profiles of obesity,  
 328 weight gain, and quality of life in idiopathic intracranial hypertension (pseudotumor cerebri).  
 329 *Am J Ophthalmol* 2007; **143**(4): 635-641. e631.

330

331 26. Kilgore KP, Lee MS, Leavitt JA, Mokri B, Hodge DO, Frank RD *et al*. Re-evaluating the  
 332 Incidence of Idiopathic Intracranial Hypertension in an Era of Increasing Obesity.  
 333 *Ophthalmology* 2017; **124**(5): 697-700.

334

335 27. Mean body mass index trends among adults, crude (kg/m<sup>2</sup>): Estimates by country. *World*  
 336 *Health Organisation*. 27/09/2017. Available  
 337 at: <http://apps.who.int/gho/data/node.main.BMIMEANADULTC?lang=en>. Accessed  
 338 02/06/2018, 2017.

339

340 28. Frisen L. Swelling of the optic nerve head: a staging scheme. *J Neurol, Neurosurg Psychiatry*  
 341 1982; **45**(1): 13-18.

342

343 29. Durcan FJ, Corbett JJ, Wall M. The incidence of pseudotumor cerebri. Population studies in  
 344 Iowa and Louisiana. *Arch Neurol* 1988; **45**(8): 875-877.

345



- 346 30. Wall M, Kupersmith MJ, Kieburtz KD, Corbett JJ, Feldon SE, Friedman DI *et al.* The idiopathic  
347 intracranial hypertension treatment trial: clinical profile at baseline. *JAMA Neurol* 2014;  
348 **71**(6): 693-701.
- 349
- 350 31. Bruce BB, Kedar S, Van Stavern GP, Monaghan D, Acierno MD, Braswell RA *et al.* Idiopathic  
351 intracranial hypertension in men. *Neurology* 2009; **72**(4): 304-309.
- 352
- 353 32. Kattah JC, Pula JH, Mejico LJ, McDermott MP, Kupersmith MJ, Wall M. CSF pressure,  
354 papilledema grade, and response to acetazolamide in the Idiopathic Intracranial  
355 Hypertension Treatment Trial. *J Neurol* 2015; **262**(10): 2271-2274.
- 356
- 357 33. Thambisetty M, Lavin PJ, Newman NJ, Biousse V. Fulminant idiopathic intracranial  
358 hypertension. *Neurology* 2007; **68**(3): 229-232.
- 359
- 360

Country	Mean population BMI (kg/m <sup>2</sup> )	Year	Prevalence of IIH	Incidence of IIH	Mean BMI (kg/m <sup>2</sup> )
Australia <sup>15</sup>	27.4	'17	7.9/100,000		
France <sup>16</sup>	25.6	'88			33
India <sup>17</sup>	21.8	'07			27.7
Israel <sup>18, 19</sup>	27.4	'01-'16		0.94	32.2
Italy <sup>14</sup>	26.3	'04		0.28	
Japan <sup>20</sup>	22.8	'00	1/1000,000	0.03	only 2 cases
Libya <sup>14</sup>	27.9	'93		2.2	
Portugal <sup>18</sup>	26.2	'16			34.8
Spain <sup>21</sup>	26.6	'15	1.2/100,000		73.77% obese
Sweden <sup>22</sup>	26.4	'17	1/100,000	0.65	34.4
Switzerland <sup>18</sup>	25.7	'16			36.4
Turkey <sup>18</sup>	27.9	'16			31.2
UK <sup>18, 23</sup>	27.5	'91-'11	10.9/100,000	0.51 - 1.57	39.7
US <sup>14, 16, 24, 25, 26</sup>	29.1	'98-'11	8.9/100,000	0.9	31.8-34

Table 1. Population and IIH rates of obesity. Population data from the World Health Organisation<sup>27</sup>.

Parameter	UK	US	P value
Black race	7.10%	58.90%	n/a
Proportion with severe visual loss (%)	5	15.4	0.014
HVF mean deviation (dB)	-4.74±0.40	-6.52±0.35	<0.001
CSF Opening pressure (cmH2O)	35.8±0.73	36.3±0.46	0.582
Visual acuity (logMAR)	0.085±0.02	0.152±0.01	<0.001
BMI (kg/cm <sup>2</sup> )	38.3±0.59	37.7±0.41	0.626
Proportion female (%)	95.9±1.8	94.0±1.27	0.284
Frisen grade	1 (IQR 1-2)	2 (IQR 1-3)	<0.001
Age (years)	31.7±0.51	32.8±0.58	0.17

Table 2. Summary of presenting features.

Symptoms	UK proportion (%)	US proportion (%)	p value (Chi squared)
Incidental papilledema	48.1	30.0	<0.001
Headache	85.4	65.0	<0.001
Diplopia	14.6	11.0	0.207
Nausea or vomiting	17.3	7.90	<0.001
Neck or back pain	4.86	2.86	0.208
Pulsatile tinnitus	43.2	17.2	<0.001
Transient visual obscurations	28.1	21.1	0.058
Other visual symptoms	40.0	35.0	.236

Table 3. Presenting symptoms in UK and US IIH patients.

Modelled Comparison	Effect	Effect size (95% CI)	P value
US white vs US black	Worse visual function in African American than white US patients	1.55 dB (0.27-2.83)	0.018
US white vs UK white	Non-significant difference with worse visual function in US white	0.76 dB (-0.38-1.89)	0.192
CSF opening pressure	Higher CSF pressure associated with worse visual function	0.123 dB/cmH <sub>2</sub> O (0.05-0.20)	0.001
Race * Country Interaction	UK African Caribbean visual function is better than US white	3.05 dB (0.82-5.29)	0.007

Table 4. Model output for the comparison of race, nationality and CSF opening pressure.